Abstract
Driver oncogene alterations have always been one of leading causes in the process of occurrence and development of tumors. And the effects of driver oncogene alterations on tumorigenesis and progression in different kinds of tumors have been studied heatedly. And the roles that the driver oncogenes alterations play have been elucidated clearly in previous studies. The phenomenon of concomitant driver oncogenes mutations and driver genes fusions has gained much concentration in the past two decades. And a growing number of studies reported this phenomenon, either coexistence or mutually exclusivity. Here we reviewed on the phenomenon of concomitant mutations in three common types of carcinomas—lung cancer, thyroid cancer, and leukemia, which have been studied relatively more detailed and more general compared with others.
Highlights
Genetic mutations are an important molecular background in tumors, and the most common types of alterations are point mutations and fusions
We review on the coexistence of pathogenic mutations and fusions of driver oncogenes in lung cancer, thyroid cancer and leukemia, in which
Yang et al carried out a study in Guangdong, China, which screened a total of 977 patients with non-small cell lung cancer (NSCLC) for the presence of Epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) fusion and coexistence of EGFR mutations and ALK fusion
Summary
Genetic mutations are an important molecular background in tumors, and the most common types of alterations are point mutations and fusions. Concomitant EGFR mutations and ALK fusions is the most common form among all kinds of coexistence of driver mutations and driver oncogene fusions in NSCLC.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
